Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent")…